Loading...
•
Jun 30, 2021
Theravance Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021.
Key Takeaways
Theravance Biopharma reported strong progress in the second quarter of 2021, with increased face-to-face engagements with customers driving continued sales volume and market share growth for YUPELRI.
Field team energized, increased face-to-face engagements with customers.
Continued sales volume and market share growth.
Initiating a controlled clinical study intended to provide data for a possible label update for YUPELRI.
2021 is a pivotal year for Theravance Biopharma.
Theravance
Theravance
Forward Guidance
The press release contains forward-looking statements regarding goals, plans, objectives, expectations and future events.